Stockscreener 앱 받기
13.66
2.11%
-0.295
시장 영업 전:
13.80
0.135
+0.99%
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
Market Moves: What’s the RSI of Theravance Biopharma Inc. stockLayoff News & Technical Buy Zone Confirmations - baoquankhu1.vn
B.Riley cuts Theravance Biopharma stock rating on trial failure - Investing.com Australia
TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study - TradingView
Share tumbles and jobs to go after Theravance failure - The Pharma Letter
B. Riley Financial Reiterates "Neutral" Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat
B. Riley Downgrades Theravance Biopharma to Neutral From Buy, Adjusts Price Target to $14 From $28 - marketscreener.com
Breaking Down Theravance Biopharma: 5 Analysts Share Their Views - Benzinga
This Vulcan Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
TBPH Analyst: HC Wainwright & Co. Lowers Price Target to $15 | T - GuruFocus
Theravance Biopharma (TBPH) Downgraded by B. Riley Securities to Neutral | TBPH Stock News - GuruFocus
Theravance to cut costs 60% after drug trial fails primary endpoint - Investing.com Canada
BTIG Maintains Buy on Theravance Biopharma, Inc. (TBPH) March 2026 - Meyka
Theravance Biopharma (TBPH): BTIG Lowers Price Target to $21.00 - GuruFocus
Theravance Biopharma Target of Unusually High Options Trading (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma (TBPH) Phase 3 Study Misses Expectations - GuruFocus
Theravance Biopharma, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Resilience - Markets Mojo
Theravance Biopharma Plummets As Phase 3 Study Falls Short - Benzinga
Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down on Analyst Downgrade - MarketBeat
BTIG cuts Theravance Biopharma stock price target on trial miss By Investing.com - Investing.com Canada
BTIG Research Lowers Theravance Biopharma (NASDAQ:TBPH) Price Target to $21.00 - MarketBeat
Theravance slashes R&D as hypotension asset fails again - BioWorld MedTech
Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review - Yahoo Finance UK
Theravance Biopharma stock tumbles after trial failure By Investing.com - Investing.com Canada
Theravance Biopharma stock tumbles after trial failure - Investing.com
Theravance considers possible sale after drug trial setback - marketscreener.com
Theravance Biopharma (TBPH) Shuts Down Ampreloxetine Program Pos - GuruFocus
Theravance Biopharma reports Phase 3 Cypress study did not meet primary endpoint; board accelerates strategic review and announces cost reduction actions - marketscreener.com
Theravance Biopharma to Restructure After Ampreloxetine Trial Fails to Meet Endpoint - marketscreener.com
Theravance Biopharma (TBPH) Shares Plummet After Disappointing S - GuruFocus
Theravance Biopharma (TBPH) to End Ampreloxetine Program Amid St - GuruFocus
Theravance Biopharma Inc. (TBPH) shares plunged 28% in pre-market trading after the company announced that its hypertension drug failed to meet the primary endpoint in a pivotal late-stage clinical trial. - Bitget
Theravance stock in focus after trial setback (TBPH:NASDAQ) - Seeking Alpha
Theravance Biopharma Restructures After Ampreloxetine Trial Failure - TipRanks
Phase 3 failure drives Theravance (NASDAQ: TBPH) restructuring and review - Stock Titan
Theravance Biopharma Reports Phase 3 Cypress Study Did Not Meet Primary Endpoint Board Accelerates Strategic Review And Announces Cost Reduction Actions - TradingView
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions - PR Newswire
H.C. Wainwright raises Theravance Biopharma price target on trial progress - Investing.com
Theravance Biopharma (NASDAQ:TBPH) Price Target Raised to $27.00 - MarketBeat
TBPH Technical Analysis & Stock Price Forecast - Intellectia AI
Understanding the Setup: (TBPH) and Scalable Risk - Stock Traders Daily
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Evaluating A Potential 46.86% Upside - DirectorsTalk Interviews
Theravance Biopharma Experiences Valuation Adjustment Amid Strong Performance Metrics - Markets Mojo
TBPH Technical Analysis & ETF Price Forecast - Intellectia AI
TBPH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
[Form 4] Theravance Biopharma, Inc. Insider Trading Activity - Stock Titan
Can Theravance Biopharma Inc reach resistance levels soonMarket Risk Report & Weekly Chart Analysis and Guides - baoquankhu1.vn
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? - TradingView
Theravance Biopharma (TBPH) SVP has 13,929 shares withheld for RSU taxes - Stock Titan
Hillsdale Investment Management Inc. Purchases New Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Irenic Dumps Most Papa John's Shares - The Motley Fool
Theravance Biopharma Inc expected to post earnings of $1.13 a shareEarnings Preview - TradingView
Trend Review: What’s the outlook for Theravance Biopharma Inc.’s sectorWeekly Trade Report & Low Drawdown Momentum Trade Ideas - mfd.ru
Newtyn discloses 8.5% Theravance Biopharma (NASDAQ: TBPH) ownership stake - Stock Titan
The Technical Signals Behind (TBPH) That Institutions Follow - Stock Traders Daily
Will Theravance Biopharma (TBPH) beat quarterly earnings? Trading Odds & Predictions (Feb. 25, 2026) - Polymarket
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Navigating a 37.70% Potential Upside in Biotechnology - DirectorsTalk Interviews
How Theravance Biopharma Inc. stock reacts to inflationary pressures2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
What’s the outlook for Theravance Biopharma Inc.’s sectorMarket Performance Summary & Free Safe Entry Trade Signal Reports - mfd.ru
Baader Bank Aktiengesellschaft Invests $781,000 in Theravance Biopharma, Inc. $TBPH - MarketBeat
How Theravance Biopharma Inc. (0TB) stock correlates with oil marketsJuly 2025 Price Swings & Verified Momentum Stock Ideas - mfd.ru
Is Theravance Biopharma Inc. stock a dividend growth opportunityJuly 2025 Sector Moves & Weekly Setup with ROI Potential - mfd.ru
Theravance Biopharma Inc (NASDAQ:TBPH) Shows Strong Technical and Fundamental Momentum - ChartMill
Is Theravance Biopharma Inc. stock showing strong momentumJuly 2025 Macro Moves & Weekly Setup with ROI Potential - mfd.ru
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
0.11%
6.00%
자본화:
|
볼륨(24시간):